Study of Two Doses of Pembrolizumab (MK-3475) Versus Docetaxel in Previously Treated Participants With Non-Small Cell Lung Cancer (MK-3475-010/KEYNOTE-010)
PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment
1,034
Participants
Timeline
Start Date
August 9, 2013
Primary Completion Date
September 30, 2015
Study Completion Date
September 30, 2020
Conditions
Non Small Cell Lung Cancer (NSCLC)
Interventions
BIOLOGICAL
Pembrolizumab
IV infusion
DRUG
Docetaxel
IV infusion
All Listed Sponsors
lead
Merck Sharp & Dohme LLC
INDUSTRY
NCT01905657 - Study of Two Doses of Pembrolizumab (MK-3475) Versus Docetaxel in Previously Treated Participants With Non-Small Cell Lung Cancer (MK-3475-010/KEYNOTE-010) | Biotech Hunter | Biotech Hunter